| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lifecome Biochemistry Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.60 |
| 52 Week High | CN¥33.00 |
| 52 Week Low | CN¥11.00 |
| Beta | 0.74 |
| 11 Month Change | 8.64% |
| 3 Month Change | 22.33% |
| 1 Year Change | -33.31% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002868 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 5.2% | -3.4% | -0.7% |
| 1Y | -33.3% | -17.6% | 3.0% |
Return vs Industry: 002868 underperformed the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 002868 underperformed the CN Market which returned 3% over the past year.
Price Volatility
| 002868 volatility | |
|---|---|
| 002868 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 002868 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002868's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 992 | Tanping Lai | www.pclifecome.com |
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, etc.; veterinary drugs; and food preservatives.
Lifecome Biochemistry Co.,Ltd. Fundamentals Summary
| 002868 fundamental statistics | |
|---|---|
| Market cap | CN¥2.58b |
| Earnings (TTM) | -CN¥292.72m |
| Revenue (TTM) | CN¥581.34m |
4.4x
P/S Ratio-8.8x
P/E RatioIs 002868 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002868 income statement (TTM) | |
|---|---|
| Revenue | CN¥581.34m |
| Cost of Revenue | CN¥695.43m |
| Gross Profit | -CN¥114.09m |
| Other Expenses | CN¥178.63m |
| Earnings | -CN¥292.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | -19.63% |
| Net Profit Margin | -50.35% |
| Debt/Equity Ratio | 319.5% |
How did 002868 perform over the long term?
See historical performance and comparison